Sarepta Therapeutics Inc- 詳細介紹、公司背景、業務範圍、財務數據以及市場表現

關於 Sarepta Therapeutics Inc 公司

Sarepta Therapeutics, Inc. 是一家商業階段的生物製藥公司。該公司致力於通過發現和開發針對核糖核酸 (RNA) 的療法、基因療法和其他用於治療罕見疾病的基因治療方式來幫助患者。該公司已開發了多種用於治療杜氏肌營養不良症 (Duchenne) 的獲批產品，並正在開發用於治療一系列疾病和病症的潛在治療候選藥物，包括杜氏肌營養不良症、肢帶型肌營養不良症 (LGMD) 和其他神經肌肉和中樞神經系統 (CNS) 相關疾病。該公司已開發並商業化了四種獲批的杜氏肌營養不良症治療產品：EXONDYS 51（eteplirsen）注射液（EXONDYS 51）、VYONDYS 53（golodirsen）注射液（VYONDYS 53）、AMONDYS 45（casimersen）注射液（AMONDYS 45）和ELEVIDYS。其產品線包括約40個處於不同發現、臨牀前和臨牀開發階段的項目。

公司簡介

公司代碼SRPT

公司名稱Sarepta Therapeutics Inc

上市日期Jun 04, 1997

成立日期2013

CEOMr. Douglas S. (Doug) Ingram, Esq., J.D.

員工數量1372

證券類型Ordinary Share

年結日Jun 04

公司地址215 1st St Ste 415

城市CAMBRIDGE

上市交易所NASDAQ Global Select Consolidated

國家United States of America

郵編02142-1213

電話16172744000

網址https://www.sarepta.com/

公司代碼SRPT

上市日期Jun 04, 1997

成立日期2013

公司高階主管

名稱

名稱/職務

職務

持股

持股變動

Mr. Richard J. (Rick) Barry

Independent Director

3.21M

+1.02%

Mr. Douglas S. (Doug) Ingram, Esq., J.D.

President, Chief Executive Officer, Director

390.31K

--

Dr. Louise Rodino-Klapac, Ph.D.

Executive Vice President, Chief Scientific Officer, Head of R&D

57.60K

+21.66%

Mr. Ian Michael Estepan

Chief Financial Officer, Executive Vice President

45.59K

+0.22%

Dr. Hans Lennart Rudolf Wigzell, M.D., Ph.D.

Independent Director

22.84K

-2.30%

Mr. Dallan Murray

Executive Vice President, Chief Customer Officer

21.18K

-44.29%

Cristin Rothfuss

Executive Vice President, General Counsel, Corporate Secretary

19.15K

+38.59%

Mr. Bilal Arif

Executive Vice President , Chief Technical Operations Officer

16.42K

-16.76%

Ms. Deirdre Connelly

Independent Director

--

Dr. Claude Nicaise, M.D.

Independent Director

--

名稱

名稱/職務

職務

持股

持股變動

Mr. Richard J. (Rick) Barry

Independent Director

3.21M

+1.02%

Mr. Douglas S. (Doug) Ingram, Esq., J.D.

President, Chief Executive Officer, Director

390.31K

--

Dr. Louise Rodino-Klapac, Ph.D.

Executive Vice President, Chief Scientific Officer, Head of R&D

57.60K

+21.66%

Mr. Ian Michael Estepan

Chief Financial Officer, Executive Vice President

45.59K

+0.22%

Dr. Hans Lennart Rudolf Wigzell, M.D., Ph.D.

Independent Director

22.84K

-2.30%

Mr. Dallan Murray

Executive Vice President, Chief Customer Officer

21.18K

-44.29%

收入明細

單位: USD更新時間: 4月6日週日

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

業務USD

名稱

營收

佔比

PMO Products

967.17M

50.85%

ELEVIDYS

820.79M

43.15%

collaboration and other

114.02M

5.99%

地區USD

名稱

營收

佔比

United States

1.64B

86.11%

Rest of World

150.25M

7.90%

業務

地區

業務USD

名稱

營收

佔比

PMO Products

967.17M

50.85%

ELEVIDYS

820.79M

43.15%

collaboration and other

114.02M

5.99%

股東統計

更新時間: 5月19日週一

持股股東

股東類型

持股股東

佔比

Capital International Investors

9.22%

The Vanguard Group, Inc.

9.17%

BlackRock Institutional Trust Company, N.A.

9.06%

Capital Research Global Investors

6.17%

State Street Global Advisors (US)

4.14%

Other

62.25%

持股股東

佔比

Capital International Investors

9.22%

The Vanguard Group, Inc.

9.17%

BlackRock Institutional Trust Company, N.A.

9.06%

Capital Research Global Investors

6.17%

State Street Global Advisors (US)

4.14%

Other

62.25%

股東類型

持股股東

佔比

Investment Advisor

42.91%

Investment Advisor/Hedge Fund

37.22%

Hedge Fund

9.45%

Individual Investor

4.42%

Research Firm

3.31%

Bank and Trust

1.10%

Pension Fund

1.10%

Sovereign Wealth Fund

1.09%

Venture Capital

0.33%

機構持股

更新時間: 1月20日週一

報告期間

機構數

持股數

持股佔比

持股變動

2025Q1

1045

100.62M

102.55%

-5.73M

2024Q4

1057

102.62M

105.91%

-1.51M

2024Q3

1027

96.14M

100.83%

-6.90M

2024Q2

997

94.21M

99.66%

-1.44M

2024Q1

932

88.31M

94.10%

-6.68M

2023Q4

926

87.42M

93.47%

-6.42M

2023Q3

916

88.86M

95.27%

-4.43M

2023Q2

931

87.46M

93.91%

-4.38M

2023Q1

946

86.41M

92.84%

-2.26M

2022Q4

996

84.01M

95.72%

-10.12M

股東持股明細

名稱

持股數

佔比

持股變動

變動比例

公告日期

Capital International Investors

8.70M

8.96%

+2.44M

+38.95%

Dec 31, 2024

The Vanguard Group, Inc.

9.07M

9.34%

+117.52K

+1.31%

Dec 31, 2024

BlackRock Institutional Trust Company, N.A.

8.94M

9.21%

+162.26K

+1.85%

Dec 31, 2024

Capital Research Global Investors

5.93M

6.11%

+49.00

+0.00%

Feb 28, 2025

State Street Global Advisors (US)

4.07M

4.19%

-200.90K

-4.70%

Dec 31, 2024

Janus Henderson Investors

4.33M

4.46%

-30.19K

-0.69%

Dec 31, 2024

Barry (Richard J)

3.18M

3.28%

+2.38K

+0.07%

Mar 10, 2025

Avoro Capital Advisors LLC

2.56M

2.63%

--

Dec 31, 2024

Wellington Management Company, LLP

2.07M

2.13%

-657.84K

-24.13%

Dec 31, 2024

Farallon Capital Management, L.L.C.

2.87M

2.95%

+285.10K

+11.05%

Dec 31, 2024

持股ETF

更新時間: 6月6日週五

機構名稱

佔比

Global X Genomics & Biotechnology ETF

2.35%

First Trust NYSE Arca Biotechnology Index Fund

2.26%

iShares Neuroscience and Healthcare ETF

1.65%

Tema Neuroscience and Mental Health ETF

1.2%

WisdomTree BioRevolution Fund

0.92%

Harbor Human Capital Factor Unconstrained ETF

0.87%

SPDR S&P Biotech ETF

0.82%

VanEck Biotech ETF

0.74%

Invesco S&P MidCap 400 Pure Growth ETF

0.57%

Direxion Daily S&P Biotech Bull 3X Shares

0.54%

Global X Genomics & Biotechnology ETF

佔比2.35%

First Trust NYSE Arca Biotechnology Index Fund

佔比2.26%

iShares Neuroscience and Healthcare ETF

佔比1.65%

Tema Neuroscience and Mental Health ETF

佔比1.2%

WisdomTree BioRevolution Fund

佔比0.92%

Harbor Human Capital Factor Unconstrained ETF

佔比0.87%

SPDR S&P Biotech ETF

佔比0.82%

VanEck Biotech ETF

佔比0.74%

Invesco S&P MidCap 400 Pure Growth ETF

佔比0.57%

Direxion Daily S&P Biotech Bull 3X Shares

佔比0.54%

分紅派息

近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股

公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

Sarepta Therapeutics Inc

20.940USD

Sarepta Therapeutics Inc

20.940

概覽

公司